These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Experimental study of low-molecular weight heparin on ameliorating progressive glomerulosclerosis].
    Author: Zhang H, Ji LZ, Wu K.
    Journal: Hunan Yi Ke Da Xue Xue Bao; 2001 Feb 28; 26(1):7-9. PubMed ID: 12536602.
    Abstract:
    OBJECTIVE: This article was to study the effect and mechanism of low-molecular weight heparin (LMWH) on ameliorating progressive glomerulosclerosis. METHODS: The progressive glomerulosclerosis models were established by repeated injection of adriamycin to the rats after the removal of their right kidneys. The therapeutic group was received the treatment of LMWH for six weeks. The proteinuria, blood-biochemistric, and renal pathologic lesion were investigated respectively; the sclerotic index of glomerulus were calculated and the expression of collagen IV (Col-IV), laminin, platelet-derived growth factor B(PDGF-B) and basic fibroblast growth factor (bFGF) in glomerulus were determined by immunohistochemistry simultaneously. RESULTS: LMWH not only reduced the proteinuria, elevated the serum albumin, improved the renal function, alleviated the renal pathologic lesion, and reduced the sclerotic index of glomerulus, but also significantly decreased the accumulation of Col-IV and laminin and the expression of PDGF-B and bFGF in glomerulus. CONCLUSION: LMWH may obviously ameliorate the progressive glomerulosclerosis; the decreased accumulation of mesangial matrix by inhibiting the expression of PDGF-B and bFGF in glomerulus may be one of the important mechanisms.
    [Abstract] [Full Text] [Related] [New Search]